Hansa Biopharma publishes Annual Report 2021
https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2022/Hansa-Biopharma-publishes-Annual-Report-2021/default.aspx
Despite a challenging operating environment, we were able to solidly execute on our key priorities for the year, which were to:
1. Ensure a successful launch of Idefirix® in leading transplantation centres in select European markets;
2. Initiate a pivotal study in the U.S. to support a future BLA for imlifidase in highly sensitized patients waiting for a kidney transplant; and
3. Continue to build on the strong momentum behind our efforts to advance our pipeline of drug candidates within autoimmune diseases and gene therapy.
https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2022/Hansa-Biopharma-publishes-Annual-Report-2021/default.aspx
Despite a challenging operating environment, we were able to solidly execute on our key priorities for the year, which were to:
1. Ensure a successful launch of Idefirix® in leading transplantation centres in select European markets;
2. Initiate a pivotal study in the U.S. to support a future BLA for imlifidase in highly sensitized patients waiting for a kidney transplant; and
3. Continue to build on the strong momentum behind our efforts to advance our pipeline of drug candidates within autoimmune diseases and gene therapy.
We have another exciting year ahead of us with several important milestones to be achieved across our platform and franchises. Our key priorities for the year are to:
1. Continue the successful execution of our commercial launch strategy for Idefirix® through obtaining pricing and reimbursement agreements in new key markets in Europe, making additional prioritized transplant centers clinically ready for initiation, and generating growing commercial sales.
2. Complete enrollment in the U.S. ConfIdeS trial.
3. Further advance our pipeline of drug candidates for autoimmune diseases and post transplant management by initiating a pivotal trial of imlifidase in anti-GBM disease and advancing our ongoing phase 2 trials in Antibody Mediated Rejection (AMR) and Guillian-Barré syndrome (GBS) toward first data read-outs.
1. Continue the successful execution of our commercial launch strategy for Idefirix® through obtaining pricing and reimbursement agreements in new key markets in Europe, making additional prioritized transplant centers clinically ready for initiation, and generating growing commercial sales.
2. Complete enrollment in the U.S. ConfIdeS trial.
3. Further advance our pipeline of drug candidates for autoimmune diseases and post transplant management by initiating a pivotal trial of imlifidase in anti-GBM disease and advancing our ongoing phase 2 trials in Antibody Mediated Rejection (AMR) and Guillian-Barré syndrome (GBS) toward first data read-outs.
